Kobayashi Pharmaceutical Co Stock Net Asset
| KBYPFDelisted Stock | USD 32.49 0.00 0.00% |
Kobayashi Pharmaceutical Co fundamentals help investors to digest information that contributes to Kobayashi Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Kobayashi Pink Sheet. The fundamental analysis module provides a way to measure Kobayashi Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kobayashi Pharmaceutical pink sheet.
Kobayashi |
Kobayashi Pharmaceutical Co Company Net Asset Analysis
Kobayashi Pharmaceutical's Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Kobayashi Pharmaceutical Net Asset | 252.55 B |
Most of Kobayashi Pharmaceutical's fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kobayashi Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, Kobayashi Pharmaceutical Co has a Net Asset of 252.55 B. This is much higher than that of the Consumer Defensive sector and significantly higher than that of the Household & Personal Products industry. The net asset for all United States stocks is notably lower than that of the firm.
Kobayashi Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kobayashi Pharmaceutical's direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kobayashi Pharmaceutical could also be used in its relative valuation, which is a method of valuing Kobayashi Pharmaceutical by comparing valuation metrics of similar companies.Kobayashi Pharmaceutical is currently under evaluation in net asset category among its peers.
Kobayashi Fundamentals
| Return On Equity | 0.0968 | |||
| Return On Asset | 0.0633 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 3.94 B | |||
| Shares Outstanding | 76.01 M | |||
| Shares Owned By Insiders | 34.50 % | |||
| Shares Owned By Institutions | 21.77 % | |||
| Price To Earning | 34.29 X | |||
| Price To Book | 2.85 X | |||
| Price To Sales | 0.03 X | |||
| Revenue | 155.25 B | |||
| Gross Profit | 88.77 B | |||
| EBITDA | 32.49 B | |||
| Net Income | 19.71 B | |||
| Cash And Equivalents | 116.15 B | |||
| Total Debt | 596 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 3.92 X | |||
| Book Value Per Share | 2,653 X | |||
| Cash Flow From Operations | 22.42 B | |||
| Earnings Per Share | 1.94 X | |||
| Number Of Employees | 3.45 K | |||
| Beta | 0.27 | |||
| Market Capitalization | 5.37 B | |||
| Total Asset | 252.55 B | |||
| Z Score | 5.4 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 252.55 B | |||
| Last Dividend Paid | 84.0 |
About Kobayashi Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kobayashi Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kobayashi Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kobayashi Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in Kobayashi Pink Sheet
If you are still planning to invest in Kobayashi Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kobayashi Pharmaceutical's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |